Bremelanotide

ʻO ka wehewehe pōkole:

ʻO Bremelanotide kahi peptide synthetic a me ka melanocortin receptor agonist i hoʻomohala ʻia no ka mālama ʻana i ka maʻi hypoactive sexual desire disorder (HSDD) i nā wahine premenopausal. Hoʻohana ia ma ka hoʻoulu ʻana i ka MC4R i loko o ka ʻōnaehana nūnū waena e hoʻonui i ka makemake a me ka hoʻoulu. Hana ʻia kā mākou API Bremelanotide maʻemaʻe kiʻekiʻe ma o ka solid-phase peptide synthesis (SPPS) ma lalo o nā kūlana koʻikoʻi koʻikoʻi, kūpono no nā hoʻoheheʻe injectable.

E hoʻouna i ka leka uila iā mākou

Huahana Huahana

API no Bremelanotide

Bremelanotidehe mea syntheticmelanocortin receptor agonistkūkulu ʻia no ka mālama ʻana iʻO ka maʻi makemake moe kolohe (HSDD) in wahine premenopausal. ʻOiai ʻo ka lāʻau lapaʻau waena mua i ʻae ʻia no HSDD, ʻo Bremelanotide kahi holomua nui i ke olakino wahine.

Ua ʻae ʻia e ka US FDA ma 2019 ma lalo o ka inoa inoaVyleesi, Hāʻawi ʻo Bremelanotide i kahi hoʻonā maʻamau, non-hormonal solution no nā wahine e ʻike nei i ka nele o ka makemake i ka moekolohe, ʻaʻole hiki ke wehewehe ʻia e nā pilikia olakino, noʻonoʻo, a i ʻole pili pili.

ʻO kā mākouAPI no Bremelanotidehana ʻia ma o ka solid-phase peptide synthesis (SPPS), e hōʻoiaʻiʻo ana i ka maʻemaʻe kiʻekiʻe, nā haumia haʻahaʻa, a me ke kūpaʻa kūpono no ka hoʻokumu ʻana i nā lāʻau lapaʻau a me nā ʻoihana.

Mechanism of Action

Hana ʻia ʻo Bremelanotide eka hoʻoulu ʻana i nā melanocortin receptors, ʻoi akuMC4R (melanocortin-4 receptor)i kaʻōnaeʻa waena. Manaʻo ʻia kēia hana e hoʻololi i nā ala i kahypothalamusnā mea e pili ana i ka moe kolohe a me ka makemake.

Loaʻa nā hopena koʻikoʻi:

Hoʻonui ʻiahōʻailona dopaminergic, e paipai ana i ka makemake moe kolohe
Hoʻopau i nā ala paʻa e pili ana i ka libido
ʻO ka hoʻololi ʻana o ka ʻōnaehana ʻōpū waename ka hilinaʻi ʻole i nā hormones sex (non-estrogenic, non-testosterone)

Hoʻokaʻawale kēia ʻano hana iā Bremelanotide mai nā lāʻau lapaʻau hormonal kuʻuna a kūpono no ka lehulehu o nā wahine.

Noiʻi a me nā hopena

Ua loiloi ʻia ʻo Bremelanotide i nā mea he nuiNā hoʻokolohua lapaʻau ma ka Phase 2 a me ka Phase 3, e pili ana i nā kaukani wahine i loaʻa i ka HSDD.

Loaʻa nā ʻike nui:

Hoʻomaikaʻi koʻikoʻi i ka helu helui nā helu makemake moe kolohe (ana ʻia e FSFI-d)
Hoʻemi i ka pilikia pili i ka makemake moe kolohe haʻahaʻa (ana ʻia e FSDS-DAO)
Hoomaka koke ka hana(i loko o nā hola), ʻaehoʻohana ma ke koi ma mua o ka hana moekolohe
Hōʻike ʻia ka maikaʻi i nā wahineme ka ʻole o nā kūlana comorbid(e laʻa, kaumaha, hopohopo)

Ma nā haʻawina lāʻau lapaʻau, a hiki i25%–35%ʻO ka poʻe maʻi i ʻike i ka hoʻomaikaʻi maikaʻi ʻana me ka placebo.

Ka palekana a me ka hoʻomanawanui

Loaʻa nā hopena ʻaoʻao maʻamaunausea, ʻūlū ʻana, apoʻo poʻo—maʻa maʻamau a paʻa iā ʻoe iho.
ʻAʻole like me nā mea hana melanocortin mua, ʻo Bremelanotideʻaʻole pili me ka piʻi nui o ke koko a i ʻole ka puʻuwaii ka nui o nā maʻi.
Ma ke ʻano he lāʻau lapaʻau e koi ʻia, pale ia i ka ʻike ʻana i ka hormone mau loa a hiki ke hoʻohana maʻalahi.

Hana ʻana a me ka maikaʻi

ʻO kā mākouAPI no Bremelanotide:

Hoʻopili ʻia me ka hoʻohana ʻana i ka SPPS kiʻekiʻe me ka hana kiʻekiʻe
Hoʻokō i nā kūlana honua koʻikoʻi noka maʻemaʻe, ka ʻike, a me nā mea hoʻoheheʻe koena
He kūpono ia no ka hoʻoheheʻe ʻia ʻana (e like me nā peni autoinjector prefilled)
Loaʻa mapailaka a me nā pūʻulu pāʻoihana, e kākoʻo ana i ka R&D a me ka lako mākeke